ClinicalTrials.gg
RecruitingNCT06909578MOCA IIUpdated Nov 20, 2026

Microvascular Obstruction Diagnosis Using the CoFI™ System Assessment - II

An interventional study of CorFlow Controlled Flow Infusion System - CoFI™ in Microvascular Obstruction (MVO), STEMI - ST Elevation Myocardial Infarction and PPCI, sponsored by CorFlow Therapeutics AG. Recruiting at 25 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by CorFlow Therapeutics AG · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 20, 2026Now RecruitingFirst sites in 5 new countries+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
236
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in ST Elevation Myocardial Infarction with a site in United States — 6 open to participants now, 11 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · United States.

Planned enrollment
22nd of 56
236 · median 101
Started
2025
with 3 others
No phase
23 of 83
3 open now
Primary completion
2026-12
later than 4 of 10 live
Registered
82nd of 83
by date

Among the 83 studies in ST Elevation Myocardial Infarction with a site in United States, this one is the 22nd largest by planned enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2025, is one of 23 with no phase, reaches primary completion later than 4 of the 10 other live ones, and was the 82nd registered.

ST Elevation Myocardial Infarction

855 studies on the registry are indexed under ST Elevation Myocardial Infarction; 201 are open to participants now.

Browse ST Elevation Myocardial Infarction studies →

Open to participants now

6 of the 83 studies in ST Elevation Myocardial Infarction with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 ST Elevation Myocardial Infarction studies recruiting now, 78 (63%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in ST Elevation Myocardial Infarction with a site in United States, or all of them as a file.
02

Study summary

A prospective, multicenter, international single-arm, pivotal clinical study designed to validate the performance of the CoFI system in detecting MVO in STEMI subjects, as confirmed by CMRI. The study will be conducted in accordance with the Declaration of Helsinki, EN ISO 14155:2020, local and national regulations.

Each study site will receive support from a sponsor-certified proctor during the learning curve to ensure consistent and accurate application of the CoFI system.

Read the detailed description

Microvascular obstruction (MVO) is a common complication that occurs after establishing coronary vessel patency by percutaneous coronary intervention (PCI) for the treatment of acute myocardial infarction (AMI).

Despite the successful restoration of vessel patency through PCI, 50% to 70% of STEMI subjects experience MVO, which affects vessels in the myocardial microcirculation. MVO occurs most commonly in the setting of AMI because the prolonged ischemia leads to endothelial damage, myocyte oedema and micro-vascular dysfunction.

Research has shown that MVO increases the risk of poor clinical outcomes, including death, re-infarction, reduced left ventricular ejection fraction (LVEF), left ventricular (LV) remodeling, heart failure, and more.

Late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) is the current state-of-the-art for MVO identification and quantification. However, due to clinical reasons, CMRI imaging cannot be performed during the subject's emergent state. In most cases, this means that the diagnosis is made outside the biological window where MVO-related damage to heart muscle could be reversed or at least reduced.

Thus, although CMRI is the most accurate method to diagnose MVO, its use in routine practice is limited. Therefore, a direct and accurate quantitative diagno-sis during primary PCI is required for early risk stratification in routine clinical practice.

The Controlled Flow Infusion (CoFI) system is designed to be integrated into current PCI protocols, enabling the rapid and safe detection of MVO after successful PCI procedures. Using a proprietary algorithm, the system can provide an output for diagnosing microvascular obstruction (MVO) immediately post-PCI by measuring real-time distal coronary back-pressure response to a dynamic infusion sequence downstream of a low-pressure occlusion balloon.

The aim of the study is to validate the pCoFI threshold of 124 mmHg to be an accurate diagnostic method for the detection of MVO in STEMI subjects following PPCI as measured in CMRI 1-3 days post-procedure.

Phase 1 is designed to evaluate the CoFI system and associated study procedures at up to eight selected sites across the United States and Europe. A minimum of 15 subjects per protocol will be included, with enrollment of up to 20 subjects.

Following analysis of the subject data in Phase 1 and confirmation to proceed by the DSMB the study will progress to Phase 2, the pivotal Phase. The aim of Phase 2 is to confirm the study hypothesis and the primary efficacy and safety endpoints to be met.

The sample size for the MOCA II Phase 2 is based on a conservative assumed prevalence of 50% MVO+. A one-time, blinded sample size re-estimation will be conducted after approximately 50% of the initially planned Phase 2 evaluable subjects have completed CMRI assessment (1-3 days after PPCI). The observed CMRI-derived prevalence of MVO+ will be used to update the assumed prevalence (i.e 50%) and recalculate the total required sample size. The final Phase 2 analysis will be conducted following confirmed database lock and ap-proval to proceed by the study DSMB.

The analyses in Phase 1 and Phase 2 will be done independently of each other. The Phase 1 analysis will be conducted by statistician (A), while statistician (B) will perform the Phase 2 analyses.

03

Conditions studied

  • Microvascular Obstruction (MVO)
  • STEMI - ST Elevation Myocardial Infarction
  • PPCI
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Clinical:

  1. Subject ≥18 years of age
  2. Ability to provide written according to GCP and governing regulations
  3. Diagnosis of acute anterior STEMI
  4. First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic

1. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation.

Exclusion Criteria

Clinical:

  1. Cardiogenic shock
  2. Thrombolytic therapy administered for this STEMI
  3. to CMRI

    1. Cardiac pacemaker or implantable defibrillator;
    2. Non-MRI compatible aneurysm clip;
    3. Neural Stimulator (i.e., TENS unit);
    4. Any implanted or magnetically activated device (insulin pump);
    5. Any type of non-MRI compatible ear implant;
    6. Metal shavings in the orbits;
    7. Any metallic foreign body, shrapnel, or bullet in a location which the physician feels would present a risk to the subject;
    8. Any history indicating contraindication to MRI
    9. Inability to follow breath hold instructions or to maintain a breath hold for >15 seconds; and
    10. Known or contraindication to gadolinium con-trast.
  4. Subject with previous Q-Wave MI and/or known cardiomyopathy (ischemic and non ischemic), ventricular pseudoaneurysm, Ventricular Septal Defect, severe mitral valve regurgitation (with or without papillary muscle rupture), severe known cardiac valvular stenosis or insufficiency, pericardial disease
  5. Major bleeding ≤ 30d prior to intervention
  6. Major surgery ≤ 30d prior to intervention
  7. or stroke ≤ 30d prior to intervention
  8. Heart failure with inotrope support and/or consideration for LVAD or heart transplant
  9. Presence of an intra-aortic balloon pump
  10. Known severe renal disease with creatinine > 2.5 mg/dL and/or \< 30 mL/min/1.73 m2
  11. Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the CIP, confound the data interpretation, or is associated with limited of less than one year
  12. Current participation in another clinical study
  13. Pregnancy

PPCI \& Angiographic:

  1. CABG of LAD
  2. Unsuitable target vessel anatomy (excessive tortuosity, diffuse disease, or moderate/heavy calcification)
  3. Cardiac condition preventing the use of the CoFI System
  4. Any angiographic post stenting condition that according to the physician requires treatment targeting no-reflow/MVO
  5. Cardiac condition mandating elective PCI/CABG procedure prior to CMRI
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
236 participants (estimated)

Study arms

  • Other
    Adult subjects presenting with STEMI in the LAD undergoing PPCI

    Device: CorFlow Controlled Flow Infusion System - CoFI™

Interventions

  • DeviceCorFlow Controlled Flow Infusion System - CoFI™

    The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint

    Diagnostic performance is measured using the two co-primary endpoints, sensitivity and specificity of the CoFI system in detecting MVO in relation to the pre-set pCoFI threshold of 124 mmHg. The analysis will be per-protocol (PP) (primary) and the full analysis set (FAS) (secondary). The control is by LGE CMRI. Hypothesis Both Sensitivity and Specificity will be tested to meet the acceptance criteria: i. The lower bound of the 95% confidence interval (CI) for sensitivity is ≥ 70% ii. The lower bound of the 95% CI for specificity is ≥ 65% These co-primary endpoints are evaluated under a joint hypothesis-testing framework. Primary Safety Endpoint Composite of device- or procedure-related mortality, clinically driven target vessel/lesion revascularization, stent thrombosis and device- or procedure related vessel dissection assessed at 30 days, as adjudicated by the CEC.

    Time frame: From enrollment to the end of treatment at 6 Months

07

Study locations

14 of 25 sites recruiting
  • Ronald Reagan UCLA Medical Center
    Los Angeles, California 90095, United States
    Recruiting
  • ChristianaCare - Christiana Hospital
    Newark, Delaware 19718, United States
    Recruiting
  • Advocate Good Samaritan Hospital
    Downers Grove, Illinois 60515, United States
    Not yet recruiting
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
    Not yet recruiting
  • Corewell Health William Beaumont University Hospital
    Royal Oak, Michigan 48073, United States
    Not yet recruiting
  • Trinity Health Ann Arbor Hospital
    Ypsilanti, Michigan 48197, United States
    Recruiting
  • Allina Health Mercy Hospital
    Coon Rapids, Minnesota 55433, United States
    Recruiting
  • Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
    Recruiting
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
  • Atrium Health Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
    Recruiting
  • The Christ Hospital
    Cincinnati, Ohio 45219, United States
    Recruiting
  • OhioHealth Riverside Methodist Hospital
    Columbus, Ohio 43214, United States
    Recruiting
  • WVU Medicine - J.W. Ruby Memorial Hospital
    Morgantown, West Virginia 26506, United States
    Recruiting
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
    Recruiting
  • University Hospital of Ferrara - Sant'Anna Hospital
    Ferrara, 44124 Cona, Italy
    Not yet recruiting
  • Humanitas Research Hospital
    Milan, 20089 Rozzano, Italy
    Not yet recruiting
  • Monzino Cardiology Center
    Milan, 20138, Italy
    Not yet recruiting
  • Umberto I University Hospital - Sapienza University of Rome
    Rome, 00161, Italy
    Not yet recruiting
  • City of Health and Science University Hospital of Turin - Molinette Hospital
    Turin, 10126, Italy
    Not yet recruiting
  • Integrated University Hospital of Verona - Borgo Trento Hospital
    Verona, 37126, Italy
    Not yet recruiting
  • The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos
    Kaunas, 50161, Lithuania
    Recruiting
  • Vilnius University Hospital Santariskiu Klinikos
    Vilnius, 08661, Lithuania
    Recruiting
  • Dedinje Institute for Cardiovascular Diseases
    Belgrade, 11040, Serbia
    Not yet recruiting
  • Valjevo General Hospital
    Valjevo, 14000, Serbia
    Not yet recruiting
  • Cardiocentro Ticino
    Lugano, Canton Ticino 6900, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Decide has to made by study leadership.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 145 interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 15 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Dec 2027, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2025
First posted
Apr 3, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
25 sites added — first sites in Italy, Lithuania, Serbia, Switzerland and United States
Show 25 added (14 United States, 6 Italy, 2 Lithuania, 2 Serbia, 1 Switzerland)
  • Ronald Reagan UCLA Medical Center · Los Angeles, United States
  • ChristianaCare - Christiana Hospital · Newark, United States
  • Advocate Good Samaritan Hospital · Downers Grove, United States
  • Henry Ford Hospital · Detroit, United States
  • Corewell Health William Beaumont University Hospital · Royal Oak, United States
  • Trinity Health Ann Arbor Hospital · Ypsilanti, United States
  • Allina Health Mercy Hospital · Coon Rapids, United States
  • Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital · Minneapolis, United States
  • Montefiore Medical Center · The Bronx, United States
  • Atrium Health Carolinas Medical Center · Charlotte, United States
  • The Christ Hospital · Cincinnati, United States
  • OhioHealth Riverside Methodist Hospital · Columbus, United States
  • WVU Medicine - J.W. Ruby Memorial Hospital · Morgantown, United States
  • Aurora St. Luke's Medical Center · Milwaukee, United States
  • University Hospital of Ferrara - Sant'Anna Hospital · Ferrara, Italy
  • Humanitas Research Hospital · Milan, Italy
  • Monzino Cardiology Center · Milan, Italy
  • Umberto I University Hospital - Sapienza University of Rome · Rome, Italy
  • City of Health and Science University Hospital of Turin - Molinette Hospital · Turin, Italy
  • Integrated University Hospital of Verona - Borgo Trento Hospital · Verona, Italy
  • The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos · Kaunas, Lithuania
  • Vilnius University Hospital Santariskiu Klinikos · Vilnius, Lithuania
  • Dedinje Institute for Cardiovascular Diseases · Belgrade, Serbia
  • Valjevo General Hospital · Valjevo, Serbia
  • Cardiocentro Ticino · Lugano, Switzerland
Nov 20, 2026
Primary completion
Dec 1, 2026→Dec 31, 2026
Nov 20, 2026
Study completion
Dec 1, 2026→Dec 31, 2027
Nov 20, 2026
Enrollment
200→236
Nov 20, 2026
Eligibility
4 inclusion criteria removed; 1 exclusion criterion removed; 5 criteria edited, 2 added
What changed in the criteria
  • ChangedBefore Persistent symptoms to balloon time ≤ 6 hours. The assessment by the treating investigator after evaluation by subjects explanation is the defining timepoint for symptom onset.Now First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic
  • Edited1. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by <50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation.
  • AddedExclusion Criteria
  • EditedKnown hypersensitivity or contraindication to gadolinium contrastcon-trast.
  • EditedSubject with previous Q-Wave MI and/or known cardiomyopathy (ischemic and non ischemic), ventricular pseudoaneurysm, VSDVentricular Septal Defect, severe mitral valve regurgitation (with or without papillary muscle rupture), severe known cardiac valvular stenosis or insufficiency, pericardial disease
  • AddedPresence of an intra-aortic balloon pump
  • EditedAny angiographic post stenting condition that according to the physician implies soc administration of any GpIIbrequires treatment targeting no-reflow/IIIa inhibitors or adenosineMVO
Inclusion criteria
  • RemovedCulprit lesion in the LAD
  • RemovedCOFI ballon can be placed according to IFU
  • RemovedRequired stent diameter ≥ 2.75 mm and ≤ 5mm
  • RemovedRequired stent length ≥ 15 mm
Exclusion criteria
  • RemovedPPCI \& Angiographic:
Nov 20, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPrimary Effectiveness Endpoint: how it is measured was reworded
Nov 20, 2026
Contact
Study contact changed: r•••@corflow.ch · •••1252→r•••@corflow.com · •••1252. See the current contact
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    25 sites added — first sites in Italy, Lithuania, Serbia, Switzerland and United States
    Show 25 added (14 United States, 6 Italy, 2 Lithuania, 2 Serbia, 1 Switzerland)
    • Ronald Reagan UCLA Medical Center · Los Angeles, United States
    • ChristianaCare - Christiana Hospital · Newark, United States
    • Advocate Good Samaritan Hospital · Downers Grove, United States
    • Henry Ford Hospital · Detroit, United States
    • Corewell Health William Beaumont University Hospital · Royal Oak, United States
    • Trinity Health Ann Arbor Hospital · Ypsilanti, United States
    • Allina Health Mercy Hospital · Coon Rapids, United States
    • Allina Health Minneapolis Heart Institute at Abbott Northwestern Hospital · Minneapolis, United States
    • Montefiore Medical Center · The Bronx, United States
    • Atrium Health Carolinas Medical Center · Charlotte, United States
    • The Christ Hospital · Cincinnati, United States
    • OhioHealth Riverside Methodist Hospital · Columbus, United States
    • WVU Medicine - J.W. Ruby Memorial Hospital · Morgantown, United States
    • Aurora St. Luke's Medical Center · Milwaukee, United States
    • University Hospital of Ferrara - Sant'Anna Hospital · Ferrara, Italy
    • Humanitas Research Hospital · Milan, Italy
    • Monzino Cardiology Center · Milan, Italy
    • Umberto I University Hospital - Sapienza University of Rome · Rome, Italy
    • City of Health and Science University Hospital of Turin - Molinette Hospital · Turin, Italy
    • Integrated University Hospital of Verona - Borgo Trento Hospital · Verona, Italy
    • The Hospital of Lithuanian University of Health Sciences (LSMU) Kauno klinikos · Kaunas, Lithuania
    • Vilnius University Hospital Santariskiu Klinikos · Vilnius, Lithuania
    • Dedinje Institute for Cardiovascular Diseases · Belgrade, Serbia
    • Valjevo General Hospital · Valjevo, Serbia
    • Cardiocentro Ticino · Lugano, Switzerland
    Primary completion Dec 1, 2026→Dec 31, 2026
    Study completion Dec 1, 2026→Dec 31, 2027
    Enrollment 200→236
    Eligibility 4 inclusion criteria removed; 1 exclusion criterion removed; 5 criteria edited, 2 added
    What changed in the criteria
    • ChangedBefore Persistent symptoms to balloon time ≤ 6 hours. The assessment by the treating investigator after evaluation by subjects explanation is the defining timepoint for symptom onset.Now First Medical Contact (FMC) to balloon time ≤ 6 hours. PPCI \& Angiographic
    • Edited1. Culprit lesion in the LAD 2. COFI ballon can be placed according to IFU 3. Required stent diameter ≥ 2.75 mm and ≤ 5mm 4. Required stent length ≥ 15 mm 5. Successful PPCI Procedure as documented by <50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no presence of a post-intervention non-stented coronary dissection or perforation.
    • AddedExclusion Criteria
    • EditedKnown hypersensitivity or contraindication to gadolinium contrastcon-trast.
    • EditedSubject with previous Q-Wave MI and/or known cardiomyopathy (ischemic and non ischemic), ventricular pseudoaneurysm, VSDVentricular Septal Defect, severe mitral valve regurgitation (with or without papillary muscle rupture), severe known cardiac valvular stenosis or insufficiency, pericardial disease
    • AddedPresence of an intra-aortic balloon pump
    • EditedAny angiographic post stenting condition that according to the physician implies soc administration of any GpIIbrequires treatment targeting no-reflow/IIIa inhibitors or adenosineMVO
    Inclusion criteria
    • RemovedCulprit lesion in the LAD
    • RemovedCOFI ballon can be placed according to IFU
    • RemovedRequired stent diameter ≥ 2.75 mm and ≤ 5mm
    • RemovedRequired stent length ≥ 15 mm
    Exclusion criteria
    • RemovedPPCI \& Angiographic:
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPrimary Effectiveness Endpoint: how it is measured was reworded
    Contact Study contact changed: r•••@corflow.ch · •••1252→r•••@corflow.com · •••1252. See the current contact
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06909578
Lead sponsor
CorFlow Therapeutics AG
Responsible party
Sponsor
First posted
Apr 3, 2025
Start date
Sep 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Reginald Walton, MBA
Contact
rwalton@corflow.com
254-424-1252

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion